TSLP Expression: Cellular Sources, Triggers, and Regulatory Mechanisms  by Takai, Toshiro
Allergology International Vol 61, No1, 2012 www.jsaweb.jp 3
Review Series: TSLP
TSLP Expression: Cellular Sources,
Triggers, and Regulatory Mechanisms
Toshiro Takai1
ABSTRACT
Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine initially identified in the culture supernatant of a
thymic stromal cell line. Highly expressed in the epidermis in skin lesions of atopic dermatitis patients, TSLP
was subsequently found to be a critical factor linking responses at interfaces between the body and environ-
ment (skin, airway, gut, ocular tissues, and so on) to Th2 responses. Recent studies have revealed that various
cell types other than epithelial cells and epidermal keratinocytes (such as mast cells, airway smooth muscle
cells, fibroblasts, dendritic cells, trophoblasts, and cancer or cancer-associated cells) also express TSLP. Envi-
ronmental factors such as Toll-like receptor ligands, a Nod2 ligand, viruses, microbes, allergen sources,
helminths, diesel exhaust, cigarette smoke, and chemicals trigger TSLP production. Proinflammatory cytoki-
nes, Th2-related cytokines, and IgE also induce or enhance TSLP production, indicating cycles of amplification.
Skin barrier injury, increased epidermal endogenous protease activity, and less epidermal Notch signaling, all
of which have been reported in atopic dermatitis, and keratinocyte-specific loss of retinoid X receptors and
treatment of skin with agonists for vitamin D receptor in mice induce TSLP production, Th2 response, or atopic
dermatitis-like inflammation. The transcription factors NF-κB and AP-1, nuclear receptors, single nucleotide
polymorphisms, microRNAs, and the peptidyl-proryl isomerase Pin1 regulate TSLP mRNA expression tran-
scriptionally or posttranscriptionally. This review focuses on events upstream of TSLP production, which is criti-
cal in allergic diseases and important in other TSLP-related disorders i.e. production sites, cellular sources, en-
vironmental and endogenous triggers and regulatory factors, and regulatory mechanisms of gene expression.
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INTRODUCTION
Thymic stromal lymphopoietin (TSLP) is an IL-7-like
cytokine initially identified in the culture supernatant
of a mouse thymic stromal cell line.1-4 This cytokine
is a critical factor linking responses at interfaces be-
tween the body and environment (skin, airway, gut,
ocular tissues, and so on) to Th2 responses.5-9 TSLP
is expressed mainly by epithelial cells (ECs) and epi-
dermal keratinocytes (KCs). Recent studies revealed
that other types of cells such as mast cells, smooth
muscle cells, fibroblasts, dendritic cells (DCs), tro-
phoblasts, and cancer or cancer-associated cells also
express TSLP. Information on the environmental, en-
dogenous, and transcriptional regulatory mecha-
nisms of TSLP expression is essential for elucidating
the pathogenesis of allergic diseases and other TSLP-
related disorders and for developing new approaches
in prevention and therapy. This review focuses on
TSLP expression including production sites, cellular
sources, environmental and endogenous triggers and
regulatory factors, and regulatory mechanisms of
TSLP gene expression.
PRODUCTION SITES AND CELLULAR
SOURCES OF TSLP
TSLP produced in response to both environmental
and endogenous factors contributes to disorders
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Fig.　1　TSLP produced in response to environmental and endogenous factors contributes to disorders and homeostasis. 
TSLP is expressed mainly by epithelial cells (ECs) and keratinocytes (KC) at barrier surfaces and is constitutively expressed 
in the thymus and intestinal ECs. TSLP expression in the epidermis, epithelium, and submucosa in skin, airway, and ocular 
tissues plays a critical role in the pathogenesis of allergic diseases. Constitutive expression in the human thymus is responsi-
ble for the differentiation of Treg cells, and that in intestinal ECs via interaction with intestinal commensal microfl ora may con-
tribute to intestinal homeostasis, a loss of which is observed in patients with Crohn disease. TSLP expressed in trophoblasts 
may contribute to maternal-fetal tolerance. TSLP expression in the tumor microenvironment contributes to tumor growth. 
TSLP expressed in synovial fl uid may have a role in rheumatoid arthritis. Red: Disorders. Blue: Homeostasis.
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and homeostasis (Fig. 1). TSLP is expressed mainly
by ECs and KCs at barrier surfaces. Its expression in
the epidermis, epithelium, and submucosa in skin,
airway, and ocular tissues plays a critical role in the
sensitization process and exacerbation of allergic dis-
eases. An initial analysis by real-time quantitative
PCR in a panel of cDNA libraries from different cells
or cell lines and a panel of purified primary cells indi-
cated that KCs, ECs, smooth muscle cells, and lung
fibroblasts, cultured in growth medium and stem cell-
derived mast cells activated by cross-linking of high-
affinity IgE receptors (FcεRI) express TSLP mRNA in
large amounts.10 Airway smooth muscle cells
(ASMCs) activated by IL-4, IL-13, and TNF-α and
KCs activated by TNF-α and IL-1β expressed higher
TSLP mRNA levels than cells cultured in medium
alone. Recent studies also have reported that not only
KCs and ECs but also various other cell types can ex-
press TSLP mRNA andor protein (Fig. 2).
THYMUS
TSLP was initially identified in the culture superna-
tant of the mouse thymic stromal cell line Z210R.1.1,2
In human thymus, TSLP is selectively expressed by
ECs of Hassall’s corpuscles within the thymic me-
dulla.11 The constitutive expression is responsible for
the differentiation of Treg cells by modulating the ac-
tivity of thymic DCs.
GUT
Taylor et al.12 reported that TSLP is expressed consti-
tutively in intestinal ECs, with its highest levels in
colonic ECs. Primary intestinal ECs from healthy
subjects but not patients with Crohn disease constitu-
tively expressed TSLP.13,14 The TSLP expressed in in-
testinal ECs may be involved in tolerance to commen-
sal microflora through modulation of DC function. In-
flamed mucosal lesions from ulcerative colitis pa-
tients had higher levels of TSLP mRNA than unin-
flamed mucosa and normal controls.15 Cultured hu-
man intestinal ECs produced TSLP without stimuli13
or in response to stimulation in vitro.16
TSLP immunoreactivity is detected in mucosal le-
sions from patients with Helicobacter pylori-infected
follicular gastritis.17 Human gastric ECs produce
TSLP in response to stimuli in vitro.17
TSLP mRNA was overexpressed in esophagal bi-
opsy samples from individuals with eosinophilic
esophagitis.18 Human esophageal ECs expressed
TSLP mRNA in response to stimulation in vitro.19
Mechanism of TSLP Expression
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Fig.　2　Regulation of TSLP expression by cytokines and IgE. Positive and negative 
regulation (induction of TSLP mRNA or protein expression, and enhancement or inhi-
bition of TSLP expression by other stimuli) is shown (see text). Positive effects of pro-
infl ammatory cytokines (TNF-α and IL-1) and Th2 cytokines (IL-4 and IL-13) are ob-
served in various cell types. Cross-linking of FcεRI-bound IgE induces TSLP 
expression in mast cells and IgE without cross-linking induces TSLP expression in 
airway smooth muscle cells (ASMCs). Promotion of TSLP expression by IgE and Th2-
related cytokines (IL-4, IL-13, IL-25, and IL-33) indicates amplifi cation cycles. Some 
reports described inhibitory effects of IFN-γ in keratinocytes, epithelial cells, and fi bro-
blasts but a report described that IFN-γ enhanced TSLP expression induced by a 
combination of TNF-α and IL-4 in intestinal epithelial cells. Red: Promotion. Blue: In-
hibition. Broken line: Possible indirect regulation in vivo.
TSLP
production
Cellular sources
of TSLP
Keratinocytes
Epithelial cells
Mast cells
Smooth muscle cells
Fibroblasts
Dendritic cells
etc.?
TNF-D, IL-1
IL-4, IL-13
IL-25
IgE
IL-17A
TGF-E
IFN-J
IL-33
FasL
TGF-D
IFN-D, IFN-E
BREAST MILK
TSLP is present in human breast milk.20 The cellular
source is assumed to be mammary ECs. The poten-
tial roles of breast milk TSLP in the development of
the neonatal gastrointestinal tract and of allergies in
childhood remain to be determined.
AIRWAY
Ying et al.21,22 reported TSLP mRNA expression in
bronchial epithelium and submucosa in cytokeratin+
ECs, CD31+ endothelial cells, tryptase+ mast cells,
elastase+ neutrophils, and CD68+ macrophages in pa-
tients with asthma and chronic obstructive pulmo-
nary disease (COPD). Consistent with their results, a
recent report described that TSLP immunostaining in
bronchial epithelium was localized predominantly to
ECs, although occasional mast cells, macrophages,
and neutrophils were identified.23 Conversely,
Okayama et al.24 reported that 90% of bronchial mu-
cosal TSLP protein+ cells are mast cells. Zhang et al.25
reported TSLP immunoreactivity in airway smooth
muscle (ASM) bundles from patients with COPD.
Cultured human lung ECs,26,27 mast cells,24
ASMCs,25 and bronchial fibroblasts,28 produce TSLP
in response to stimulation in vitro.
Higher concentrations of TSLP in nasal lavage29
and higher levels of TSLP expression in nasal ECs30
of patients with allergic rhinitis than the control
group have been reported. Mou et al.31 reported
TSLP immunoreactivity in the pseudostratified cili-
ated columnar epithelium of nasal mucosa in patients
with allergic rhinitis and additional staining in subepi-
thelial inflammatory cells. Kimura et al.32 observed
TSLP immunoreactivity in ECs, endothelial cells, fi-
broblasts, and inflammatory cells in nasal polyps and
nasal mucosa and that the number of TSLP+ cells was
greater in nasal polyps than nasal mucosa in patients
with allergic rhinitis. Cultured human nasal ECs29
and nasal polyp fibroblasts33 produce TSLP in re-
sponse to stimuli in vitro.
Soumelis et al.10 found TSLP immunoreactivity in
crypt ECs of human inflamed tonsils and a few small
foci of TSLP expression within the apical part of the
squamous epithelium.
A recent study reported that mouse lung CD11c+
DCs expressed TSLP mRNA at an even higher level
than did epithelial cells when the animals were chal-
lenged with house dust mite extract.34 GM-CSF-
induced mouse bone marrow-derived myeloid DCs,
primary mouse splenic DCs, human monocyte-
derived DCs, and human peripheral blood monocytes
express TSLP mRNA andor produce TSLP in re-
sponse to stimulation in vitro.
SKIN
Soumelis et al.10 found TSLP to be expressed in KCs
of the apical layers of the epidermis in skin lesions of
acute and chronic atopic dermatitis (AD) patients but
not in nonlesional skin and not in lesions of patients
with nickel-induced allergy contact dermatitis or cuta-
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neous lupus erythematosus. Human skin explants,35
cultured epidermal KCs,36 and dermal fibroblasts37
produce TSLP in response to in vitro stimuli. In-
creased serum TSLP levels in children with AD,38 but
not in adults,39,40 have been reported, although a re-
port described increased serum TSLP concentrations
in patients with AD including adults.41
A report described that dermal TSLP expression
was induced at 1 hour after an allergen challenge in
the skin of allergic rhinitis andor asthma patients in
elastase+ neutrophils, CD31+ endothelial cells, tryp-
tase+ mast cells, and CD68+ macrophages.42
OCULAR TISSUES
Matsuda et al.43 reported TSLP expression in con-
junctival ECs of giant papillae from patients with
chronic allergic keratoconjunctivitis (vernal kerato-
conjunctivitis or atopic keratoconjunctivitis). Cultured
conjunctival ECs,44 corneal ECs, and corneoscleral
tissues45 produce TSLP in response to stimulation in
vitro.
MATERNAL-FETAL INTERFACE
Guo et al.46 reported that human trophoblasts and de-
cidual ECs at the maternal-fetal interface of early pla-
centas express TSLP mRNA and protein, but only tro-
phoblasts secrete soluble TSLP. The study suggests
that human trophoblasts may contribute to maternal-
fetal tolerance.
TUMOR MICROENVIRONMENT
Recent papers reported that TSLP expression in the
tumor microenvironment contributes to tumor
growth following intratumoral Th2 cell differentia-
tion.37,47 A report described increased serum TSLP
levels in patients with cutaneous T cell lymphomas.40
SYNOVIAL FLUID
Koyama et al.48 reported higher TSLP concentrations
in synovial fluid from patients with rheumatoid arthri-
tis than those with osteoarthritis and showed a contri-
bution of TSLP to an experimental arthritis in mice.
Synovial fibroblasts from patients with rheumatoid ar-
thritis and those with osteoarthritis produces similar
amounts of TSLP in response to in vitro stimuli.48,49
Microparticles isolated from synovial fluids induced
the release of TSLP in synovial fibroblasts from pa-
tients with rheumatoid arthritis.50
ENVIRONMENTAL TRIGGERS FOR TSLP
PRODUCTION
At barrier interfaces, environmental stimuli trigger
TSLP production (Fig. 1). Allergen exposure, viral in-
fections, microflora, helminth infections, diesel ex-
haust, cigarette smoke, and chemicals trigger TSLP
production, resulting in initiation of the sensitization
process and the exacerbation of allergic diseases. In-
duction of TSLP production through interaction with
intestinal commensal microflora may contribute to in-
testinal homeostasis.
TLR LIGANDS
Primary human airway ECs release TSLP in response
to Toll-like receptor (TLR) ligands: synthetic double-
stranded RNA (dsRNA) (polyinosinic-polycytidylic
acid, polyI:C) (TLR3 ligand), mimicking viral dsRNA,
in small airway ECs26 and bronchial ECs27; and pep-
tideglycan (PGN) (TLR2 ligand) and lipoteicoic acid
(LTA) (TLR2 ligand) in small airway ECs.26 Bronchial
ECs from patients with asthma are biased towards
higher TSLP and lower IFN-β production in response
to polyI:C.51 A report described induction of low
TSLP mRNA expression by LTA, poly(CpG) (TLR8
ligand), and CpG-B (TLR9 ligand) in primary human
bronchial ECs.52 Combinations of ovalbumin and low
or high concentrations of LPS induce TSLP mRNA
expression in primary mouse stroma cells.53
Primary human KCs36,54-56 and corneal ECs45 re-
lease TSLP in response to polyI:C, diacylated lipopep-
tide FSL-1 (TLR2-TLR6 ligand), and flagellin (TLR5
ligand). Human corneoscleral tissues produce TSLP
in response to polyI:C ex vivo.45 Primary human con-
junctival ECs express TSLP mRNA and release TSLP
in response to polyI:C.43,44
Primary human oral ECs release TSLP in response
to polyI:C.57 Primary human esophagus ECs express
increased TSLP mRNA levels in response to
polyI:C19; and human esophagus EC lines, in re-
sponse to polyI:C and zymosan (TLR2-TLR6
ligand).58 The human colonic EC line Caco-2 ex-
pressed TSLP mRNA in response to polyI:C15 and
flagellin.59
Primary human synovial fibroblasts release TSLP
in response to polyI:C and LPS.49 DCs have been re-
ported to produce TSLP in response to TLR ligands.34
Mouse bone marrow-derived myeloid DCs release
TSLP in response to CpG (TLR9 ligand), LPS, and zy-
mosan and express TSLP mRNA in response to flag-
ellin. Primary mouse splenic DCs express TSLP
mRNA in response to CpG and LPS. Human periph-
eral blood monocytes and monocyte-derived DCs
produce TSLP in response to zymosan and LPS.
Nod2 LIGAND
Intracellular nucleotide-binding oligomerization do-
main (Nod)-like receptors (NLRs) belong to another
class of pattern recognition receptors. Nod1 and
Nod2 detect motifs of bacterial peptideglycans. Meso-
diaminopimelic acid (meso-DAP) expressed by most
gram-negative bacteria and muramyl dipeptide
(MDP) expressed by most gram-positive and gram-
negative bacteria are ligands for Nod1 and Nod2, re-
spectively. Intranasal administration of the Nod2
ligand, but not the Nod1 ligand, rapidly induced lung
expression of TSLP mRNA in mice, with a peak at 3
hours.60
Mechanism of TSLP Expression
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VIRUSES
Rhinovirus RV16 induced TSLP mRNA expression in
primary human bronchial ECs27 and stimulated the
release of TSLP in bronchial ECs from COPD pa-
tients.61 Respiratory syncytal virus (RSV) enhanced
TSLP production in primary rat airway ECs.62 Influ-
enza A virus increased the amount of TSLP in the su-
pernatant of cocultures of nasal ECs from smokers
and monocyte-derived DCs from nonsmokers.63 Ve-
sicular stomatitis virus (VSV) induced the release of
TSLP in primary human KCs.64
Human immunodeficiency virus (HIV) triggered
TSLP production in a human cervical EC line, C33,
and TSLP mRNA expression in several human EC
lines (neuronal SKMN and intestinal HT-29) and pri-
mary KCs, but not in other cell types such as fibro-
blasts and T cells.65 In rhesus macaques, simian im-
munodeficiency virus (SIV) causes dramatic in-
creases in TSLP production concurrent with an in-
crease in viral replication in the vaginal tissues.65
MICROBES
An important contribution of Staphylococcus aureus,
which heavily colonizes the lesions of AD patients, to
the pathogenesis of AD has been suggested. An S.
aureusmembranous fraction stimulated the release of
TSLP in primary human KCs and the induction of
TSLP mRNA expression was dependent on TLR2 and
TLR6 mRNA expression, suggesting that S. aureus-
derived diacylated lipoproteins trigger TSLP produc-
tion.55 S. aureus-derived extracellular vesicles pro-
moted the release of TSLP in primary mouse dermal
fibroblasts.66 Malassezia yeasts, which are also mem-
bers of the cutaneous microflora and act as an exacer-
bating factor in AD, stimulated the release of TSLP in
primary human KCs, an effect inhibited by competi-
tive antagonists for lysophosphatidic acid (LPA) re-
ceptors.67
Both live and dead microorganisms stimulated the
release of TSLP in a human colonic EC line, Caco-
2.16,68 Direct contact with Helicobacter pylori pro-
moted the release of TSLP in the human gastric EC
lines, MKN45 and MKN28.17 TSLP immunoreactivity
was detected in mucosal lesions from patients with H.
pylori-infected follicular gastritis.17
ALLERGEN SOURCES
Allergen sources such as house dust mites, pollens,
fungi, and insects produce or contain proteases.69
Kouzaki et al.70 reported that prototypic proteases,
trypsin (serine protease) and papain (cysteine pro-
tease), and an extract of the airborne fungus Alter-
naria stimulated release of TSLP in a human bron-
chial epithelial cell line, BEAS-2B. The upregulation
of TSLP gene expression in BEAS-2B cells was inhib-
ited by transfection with protease-activated receptor-2
(PAR2) siRNA completely for trypsin and partially for
papain and the Alternaria extract. They also de-
scribed that trypsin, papain, the Alternaria extract
and a PAR2 agonist peptide induced TSLP mRNA ex-
pression in primary human bronchial ECs. Yu et al.71
reported that papain induced TSLP mRNA expression
in a mouse lung epithelial cell line MLE12 and pri-
mary mouse lung ECs; a mite major allergen Der p 1
with cysteine protease activity in MLE12 cells and
mouse embryonic fibroblasts (MEFs); and an Asper-
gillus oryzae protease in MEFs. Tang et al.72 reported
that the injection of papain into mouse ears induced
TSLP expression in the epidermis, which was de-
pendent on reactive oxygen species (ROS), TLR4,
and TRIF. Sokol et al.73 described that papain in-
duced TSLP mRNA expression in mouse bone
marrow-derived basophils.
Airway administration of house dust mite extract in
mice induces release of TSLP into bronchoalveolar
lavage fluid in a manner dependent on TLR4 expres-
sion in airway structural cells.74 However, a recent re-
port described that lung CD11c+ DCs expressed
TSLP mRNA at an even higher level than did ECs in
mice challenged intratracheally with house dust mite
extract.34 Administration of ragweed pollen extract to
mouse ocular surfaces induced TSLP production in
corneal and conjunctival epithelia75,76 and the release
of TSLP in primary human conjunctival ECs, both in a
TLR4-dependent manner.75 In a human skin equiva-
lent model, active scabies mites Sarcoptes scabiei on
the surface and scabies mite extract induced the re-
lease of TSLP.77
Chitin is a polysaccharide providing structural ri-
gidity to fungi, mites, insects, helminths, crustaceans,
and so on, many of which are allergen sources. Chitin
stimulated primary human KCs and a human KC line
HaCaT to release TSLP.78
HELMINTHS
Infections of mice with the intestinal-dwelling nema-
tode Trichuris muris result in upregulated TSLP
mRNA expression in the intestine.79 Helminths pro-
duce proteases and chitin,80 which as well as
allergen-derived proteases may induce TSLP expres-
sion as described above. A recent report described
that Trichinella spirals excretory proteins stimulated
TSLP mRNA expression in a mouse colon EC line,
CT-26, which was partially prevented by a serine
protease-specific protease inhibitor.81
DIESEL EXHAUST PARTICLES
Diesel exhaust particles (DEPs) stimulate the release
of TSLP in primary human bronchial ECs and mRNA
expression in a human bronchial EC line, 16HBE
14o−.82,83 DEPs increase ROS production, and DEP-
induced TSLP mRNA expression can be inhibited by
an antioxidant, N-acetyl cysteine (NAC).82
CIGARETTE SMOKE EXTRACT
Intranasal administrations of cigarette smoke extract
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(CSE) in mice induce TSLP production mainly in
bronchial ECs.84 The CSE-induced TSLP production
can be inhibited by intraperitoneal administration of
NAC. CSE stimulates TSLP production in primary hu-
man ASMCs, and the reduction in CSE-induced TSLP
production by NAC is partial.85
CHEMICALS
In mice, the treatment of skin with aromatic com-
pounds86 and dibutyl phthalate (DBP)87 induced
TSLP production in the epidermis. Intraperitoneal ad-
ministration of diisononyl phthalate (DINP) en-
hanced TSLP expression induced in the ears by in-
tradermal injection with house dust mite extract.88
Among the aromatic compounds tested, 1,3,5-
trimethylbenzene, 1,2,4-trimethylbenzene, and xylene
are volatile solvents of paints and glues and are often
detected in indoor environments. DBP is a commonly
used plasticizer and also used as an additive in adhe-
sives or printing inks. DINP is a principal plasticizer
in various polyvinyl chloride products.
12-O-tetradecanoylphorbol 13-acetate (TPA), also
known as phorbol myristate acetate (PMA), induces
TSLP production in the epidermis in mice.89 TPA
PMA plus A23187 induced TSLP mRNA expression
in a human mast cell line, HMC-1.90 TPAPMA is
known as a tumor promoter. A23187 is a calcium
ionophore.
ENDOGENOUS TRIGGERS AND REGULA-
TORS
Proinflammatory cytokines, Th2-related cytokines,
and IgE contribute to TSLP production, suggesting
amplification cycles (Fig. 2). TSLP production can be
positively or negatively regulated via nuclear recep-
tors and β2-adrenoceptor signaling, although the
mechanisms have not been fully elucidated.
Skin barrier injury, increased epidermal endoge-
nous protease activity, and less epidermal Notch sig-
naling, all of which have been reported in AD, and as
well as the KC-specific loss of retinoid X receptors,
treatment of skin with agonists for the vitamin D re-
ceptor in mice induce TSLP production and, in mice,
a Th2 response or AD-like inflammation, demonstrat-
ing that a disturbance of epidermal homeostasis trig-
gers TSLP production and the increase in TSLP con-
centrations in the epidermis induces the onset of Th2
inflammation.
Regulation by microRNAs (miRNAs) of TSLP pro-
duction in intestine and skin has been reported. The
peptydil-proryl isomerase Pin1, which maintains the
structure and activity of transcription-related pro-
teins, also contributes to TSLP production.
CYTOKINES
Cytokines can induce, enhance, or suppress TSLP
production (Fig. 2). In primary human small airway
ECs, a combination of IL-1β and TNF-α stimulated
the release of TSLP.26 In primary human bronchial
ECs, a combination of TNF-α with Th2 cytokines (IL-
4 or IL-13) stimulated the release of a small amount of
TSLP, and IL-4 or IL-13 promoted the polyI:C-induced
release of TSLP.27 In a human bronchial EC line,
BEAS2B, IL-4 and IFN-γ respectively enhanced and
inhibited the release of TSLP induced by trypsin, pa-
pain, Alternaria extract, and polyI:C.70 In the mouse
lung EC line MLE12, IL-25 (also known as IL-17E),
which is an initiator cytokine of Th2 responses,7
stimulated TSLP mRNA expression.91
In human primary nasal ECs, IL-25 and IL-17A en-
hanced and inhibited the polyI:C-induced release of
TSLP, respectively.29 In primary human nasal polyp
fibroblasts, TNF-α induced the release of TSLP; IL-4
or IL-13 enhanced the TNF-α-induced the release of
TSLP; and IFN-γ inhibited the relase of TSLP induced
by TNF-α plus IL-4 or IL-13.33 In mice, IL-13 induced
TSLP production in nasal epithelium ex vivo and in
vivo.92
In primary human ASMCs, TNF-α, IL-1α, IL-1β,
and mast cell-derived TNF-α, but not IL-4 and IL-13,
induce the release of TSLP, and IL-1β enhances the
TNF-α-induced release of TSLP.25,93 A report de-
scribed that IL-4 induces the release of TSLP in pri-
mary human bronchial ECs; TNF-α in primary hu-
man ASMCs and lung fibroblasts: and a combination
of IL-4 and TNF-α induces the highest concentration
of TSLP released in the three types of lung tissue
cells.28
Proinflammatory cytokines (TNF-α or IL-1α) with
Th2 cytokines (IL-4 or IL-13) acted synergistically to
induce TSLP production in human skin explants.35 In
primary human KCs, a combination of TNF-α and
Th2 cytokines stimulated TSLP production and pro-
moted the release of TSLP induced by polyI:C, FSL-1,
S aureus membrane, and flagellin.36,55,56 Type I IFNs
(IFN-α and IFN-β) enhanced polyI:C-induced TSLP
production.36 IFN-γ, TGF-β, andor IL17A inhibited
TSLP production induced by polyI:C, FSL-1, and S.
aureus membrane.36,55 TGF-α, a ligand for the epider-
mal growth factor receptor (EGFR), upregulated
flagellin-induced TSLP production.56 A report de-
scribed that Fas ligand (FasL) induces TSLP mRNA
expression in reconstituted human epidermis.94 Neth-
erton syndrome patients infused with the anti-TNF-α
antibody Infliximab exhibited an improvement in AD-
like symptoms and decrease of TSLP production in
skin.95 KC-specific transgenic expression of IL-13 in
mice induced TSLP production in KCs and AD-like
phenotypes.96
In primary human corneal ECs, TNF-α and IL-1β
induced the release of TSLP, and Th2 cytokines (IL-4
or IL-13) promoted the release of TSLP induced by
TNF-α, polyI:C, or flagellin.45 In human corneoscleral
tissues, TNF-α induces release of TSLP, and Th2 cy-
tokines (IL-4 or IL-13) upregulate release of TSLP in-
duced by TNF-α or polyI:C ex vivo.45
Mechanism of TSLP Expression
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In a human colonic EC line, Caco-2, a combination
of TNF-α and IL-4 induced TSLP mRNA expression
which was enhanced by IFN-γ, resulting in produc-
tion of the TSLP protein.15 In another human colonic
EC line, HT-29, IL-13 induced the expression of the
miRNA miR-375, which is responsible for TSLP
mRNA and protein production.97 Intraperitoneal injec-
tion of IL-33, an initiator cytokine of the Th2 re-
sponse,7 enhanced Trichuris muris(nematode)-
induced TSLP mRNA expression in the intestine of
mice.79
In human mast cells, priming with IL-4 enhances
TSLP mRNA expression induced by cross-linking of
high-affinity IgE receptor (FcεRI)-bound IgE, result-
ing in enhanced TSLP production.24 In GM-CSF-
induced mouse bone marrow-derived DCs, IL-4 aug-
mented TSLP production induced by CpG, LPS, and
zymosan.34 GM-CSF plus IL-4-induced human
monocyte-derived DCs produce TSLP in response to
zymosan and LPS.
In primary human cancer-associated fibroblasts,
TNF-α, IL-1β, and tumor-derived TNF-α and IL-1β
caused the release of TSLP, but had little or no effect
in primary human dermal fibroblasts from normal
skin.37 In primary human synovial fibroblasts, TNF-α
induced TSLP production48 and IFN-γ inhibited TSLP
production induced by TNF-α, LPS, or polyI:C.49
IgE
In peripheral blood-derived mast cells, cross-linking
of FcεRI-bound IgE induces TSLP mRNA expression
and priming with IL-4 augments it, resulting in en-
hanced TSLP production.24 Mast cell-derived pro-
teases, the majority of which are released within 1
hour after FcεRI aggregation, degrade the TSLP re-
leased, making the detection of TSLP in culture su-
pernatant difficult.24 Human ASMCs express FcεRI.
Interestingly, in primary human ASMCs, stimulation
with IgE without being cross-linked with anti-IgE an-
tibodies or allergens induces the release of TSLP and
the induction of TSLP mRNA expression is depend-
ent on spleen tyrosine kinase (Syk).98 These reports
suggest that IgE-TSLP exacerbates allergic diseases
(Fig. 2).
IgA
In the human intestinal EC line Caco-2 grown as po-
larized monolayers, the association of Lactobacillus or
Bifidobacterium with nonspecific secretory IgA en-
hanced probiotic adhesion and potentiated TSLP pro-
duction.99
LIPID MEDIATORS
Lysophosphatidic acid (LPA) is a bioactive lipid-
mediator, levels of which are elevated in the lungs of
patients with asthma. LPA induces the release of
TSLP in primary human bronchial ECs in a manner
dependent on CARMA3CARD10, a protein contain-
ing a caspase recruitment domain (CARD).100
Endogenous and synthetic agonists for EP3 [a sub-
type of prostaglandin E2 (PGE2) receptors], PGE2
and ONO-AE248, inhibit polyI:C-induced release of
TSLP in human conjunctival ECs.101 Previous studies
demonstrated that the PGE2-EP3 pathway sup-
presses allergic airway inflammation and contact hy-
persensitivity in mice.
REGULATION VIA β2-ADRENOCEPTOR SIGNAL-
ING
β2-adrenoceptor agonists (β2-agonists) including two
long-acting agonists (salmeterol and formoterol) and
a short-acting agonist (salbutamol) enhance the re-
lease of TSLP induced by a combination of IL-4 and
TNF-α via upregulation of intracellular cAMP in pri-
mary bronchial ECs, ASMCs, and lung fibroblasts,28
while salmeterol inhibits the polyI:C-induced release
of TSLP in primary human bronchial ECs.102
REGULATION VIA NUCLEAR RECEPTORS
Nuclear receptors belong to a superfamily of ligand-
dependent transcriptional regulators that include
ligand-dependent and orphan receptors. Within the
nuclear receptor superfamily, the retinoid X receptor
(RXR) isotypes (RXRα, β, and γ) play a key role as
heterodimeric partners for other nuclear receptors,
e.g. retinoic acid receptors (RARs), vitamin D recep-
tor (VDR), peroxisome proliferator-activated recep-
tors, and liver X activated receptor. In mice, epider-
mal KC-specific ablation of genes for RXRα and
RXRβ,103 as well as treatment of skin with physiologi-
cally active ligands for VDR [1,25-dihydroxyvitamin
D3(the active form of vitamin D3; calcitriol) and its
analog MC903 (calcipotriol; Dovonex)],104,105 results
in increased TSLP production in the skin and an AD-
like phenotype (Fig. 3, upper). 9-cis-retinoic acid (9-
cis-RA), a RXR agonist, inhibited IL-1β-induced TSLP
mRNA expression in a human bronchial EC line,
16HBEo− cells.106
Glucocorticoids (GCs), ligands of the GC re-
ceptor (GR), can inhibit TSLP production (Fig. 3, up-
per).27,49,107-109 A combination of GC and a long acting
β2-agonist, salmeterol, synergistically inhibited the
polyI:C-induced release of TSLP in primary human
bronchial ECs.102 GC can inhibit the release of TSLP
induced by cytokines plus salmetelol.28 A GC re-
sponse element (GRE) in mouse TSLP promoter can
act as a silencer element.109
BARRIER DYSFUNCTION
Skin barrier dysfunction is a critical driving force in
the initiation and exacerbation of AD and the “atopic
march” in allergic diseases.69,110-112 Injury to the stra-
tum corneum in human skin with tape stripping or a
detergent, sodium lauryl sulfate, induces TSLP pro-
duction in the epidermis.113 Injury with tape stripping
in mice induces TSLP production in skin, which po-
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Fig.　3　Transcriptional and posttranscriptional regulation of TSLP mRNA expression. 
Upper: Transcriptional regulation by transcription factors (NF-κB, AP-1, and AP-2α) 
and nuclear receptors (RXR, VDR, RAR, and GR). The regulation by RXR-RAR het-
erodimers and RXR-VDR heterodimers, both in complexes with corepressors, in the 
model proposed by Li et al.104 is not represented here (see text). Lower: Posttranscrip-
tional and/or transcriptional regulation by microRNAs (miRNAs) and Pin1. TSLP pro-
duction in intestine and skin seems to be differently (positively or negatively, respec-
tively) regulated by miRNAs (see text). GC, Glucocorticoid; GR, GC receptor; RAR, 
Retinoic acid receptor; RXR, Retinoid X receptor; VDR, Vitamin D receptor; 9-cis-RA, 
RXR agonist; BMS961, RARγ agonist; MC903, VDR agonist.
Red arrow: Promotion; Blue line: Inhibition;
Broken line: Process with possible indirect regulation
9-cis-RA
RXR IKK-E
NF-NB
GC
GR
AP1 AP-2D
?
BMS961 MC903
RAR VDR
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miRNA biogenesis
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Cis-trans isomerization of proline
residues of target proteins
Pin1
larizes skin DCs to elicit a Th2 response.114
A report described that knockdown of the expres-
sion of filaggrin, a stratum corneum structural protein
essential for skin barrier function, in the human KC
cell line HaCaT and reconstituted human epidermal
layers enhanced polyI:C-induced TSLP production.115
Knockdown of the expression of E-cadherin, an ad-
hesion molecule that mediates intercellular contact
through homophilic interactions, in the human bron-
chial EC line 16HBE 14o− induced the mRNA expres-
sion of TSLP and TARC through EGFR signaling
pathways.116
ENDOGENOUS PROTEASES
Netherton syndrome is a severe genetic skin disease
with constant atopic manifestations that is caused by
mutations in SPINK5(serine protease inhibitor Kazal-
type 5), which encodes lymphoepithelial Kazal-type
related inhibitor (LEKTI).117,118 A lack of LEKTI
causes SC detachment secondary to epidermal pro-
tease hyperactivity119 and overexpression of TSLP.120
LEKTI inhibits the protease activity of epidermal kal-
likrein (KLK) 5, KLK7, and KLK14.121 KLK5 directly
activates PAR2 to upregulate TSLP mRNA expression
and induces TSLP production in primary human
KCs.120 At embryonic day 19.5, Spink5Par2 double
knockout mice display a dramatic decrease in TSLP
expression, confirming the role of the KLK5-PAR2
cascade in TSLP-mediated early proallergic signal-
ing.122 Levels of the transcription factor Sp1 were sig-
nificantly decreased in skin biopsy samples obtained
from patients with AD.123 Knockdown of Sp1 expres-
sion in primary human KCs caused the upregulation
of KLK-related genes including KLK5, and the ele-
vated KLK activity induced TSLP production.124
Channel-activating protease-1 [CAP1; also termed
protease serine S1 family member-8 (Prss8)], the
mouse homologue of human prostasin, is a glyco-
sylphosphatidylinositol (GPI)-anchored serine pro-
tease. KC-specific transgenic expression of either
CAP1Prss8 or PAR2 in mice causes an AD-like-
disease associated with increased TSLP expression
and the former is dependent on PAR2 expression.125
CAP1Prss8 can trigger PAR2-dependent signaling
Mechanism of TSLP Expression
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but cannot directly activate PAR2. The CAP1Prss8-
induced signaling is dependent on intermediate acti-
vation of another serine protease, pro-CAP3martip-
tase, which in turn is a remarkably potent and spe-
cific activator of PAR2.
NOTCH SIGNALING
The Notch signaling pathway is a critical regulator of
epidermal integrity. Patients with AD but not psoria-
sis or lichen planus have a marked reduction of
Notch receptor expression in the skin.126 KC-specific
ablations of Notch signaling lead to higher TSLP con-
centrations and AD-like disease in mice.126-128
miRNAs
miRNAs have emerged as important regulators of
many biological processes.129,130 In a human colorec-
tal cancer cell line, HT-29, IL-13 induces the miRNA
miR-375, which induces TSLP mRNA and protein pro-
duction, indicating a Th2-amplification loop.97 In
mice, abolishing the induction of miRNAs by induc-
ible gut-specific ablation of Dicer1, which encodes
Dicer, an enzyme involved in miRNA biogenesis, re-
sults in lower levels of colon epithelial TSLP mRNA.97
Inducible epidermal KC-specific ablation of Dicer1
in mice results in an aggravated MC903-induced AD,
accompanied by an increase in TSLP production by
KCs.131 Skin of the mice with ablation of Dicer1 also
shows increased TSLP production upon topical treat-
ment with DBP. Thus, TSLP production in intestine
and skin seems to be differently regulated by miR-
NAs (Fig. 3). Identifying miRNAs implicated in the
skin and other epithelia needs to be addressed.
PEPTIDYL-PRORYL ISOMERASE Pin1
Eukaryotic transcription is regulated predominantly
by the posttranslational modification of the participat-
ing components. One such modification is the cis-
trans isomerization of peptidyl-proryl bonds by the
peptidyl-proryl isomerase Pin1 (Fig. 3, lower panel),
resulting in a conformational change in the protein in-
volved.132 Targets of Pin1 include proteins involved in
transcription or posttranscriptional steps.132,133 In rats
sensitized and challenged with ragweed pollen, the
intraperitoneal administration of juglone, a Pin1 in-
hibitor, decreased lung TSLP and bronchoalveolar
lavage cell TNF-α mRNA expression.133 In primary
mouse lung fibroblasts, juglone inhibited TSLP
mRNA and protein expression induced by IL-4 plus
TNF-α.
TRANSCRIPTIONAL REGULATION OF TSLP
GENE EXPRESSION
NF-κB activation is considered essential for TSLP
production (Fig. 3).52,134 According to the data ob-
tained by luciferase reporter assays, binding of the
transcription factor NF-κB (and also AP-1 in cultured
human ASMCs98,135) in humans and mice around -3.8
kb upstream of the TSLP transcription initiation site
is essential for inducible TSLP gene expression in
lung ECs.52,106 However, the regulation of TSLP gene
expression on the chromatin structure by nuclear re-
ceptors is more complex and has not been fully eluci-
dated.103,104,106,109 Two single nucleotide polymor-
phisms (SNPs) in the human TSLP promoter, which
are associated with disease susceptibility to asthma,
are located in transcription factor-binding motifs and
affect the binding of transcription factors to the
sites.102,136
NF-κB REGULATORY REGION AROUND -3.8 KB
5’ UPSTREAM OF THE TSLP TRANSCRIPTION
INITIATION SITE
Lee et al.52 concluded that inducible human and
mouse TSLP gene expression requires activation of
NF-κB and subsequent binding to a site around -3.8
kb upstream of the transcription initiation site (here-
after called the “NF-κB regulatory region”) on the ba-
sis of the data obtained by reporter assays using hu-
man TSLP promoter-containing luciferase reporter
plasmids. ~120 bp of the human TSLP gene promoter
from -3.74 to -3.86 kb upstream of the transcription in-
itiation site contained a cis element that was required
for IL-1β-induced promoter activity in the human
bronchial EC line 16HBEo−. The ~120 bp sequence
contained consensus binding sites for the transcrip-
tion factors NF-κB, IRF-1, and Opaque-2, and a puta-
tive binding site for AP-1. Mutation of the NF-κB mo-
tif significantly decreased the IL-1β-induced promoter
activity; mutation of the putative AP-1 motif partially
lowered the activity; and mutation of the IRF-1 or the
Opaque-2 motif had no effect. A region from -3.6 to
-3.8 kb upstream of the mouse TSLP transcription in-
itiation site, which contains two putative NF-κB mo-
tifs, was required for inducible promoter activity in
the mouse lung EC line MLE12. Mutation of the 3’
NF-κB site, but not the 5’ site, eliminated IL-1β-
mediated induction of the promoter activity. This
study also examined the deletion of two putative RXR-
binding sites upstream of the mouse TSLP gene
[base pairs -2175 to -2164 (DR1) and base pairs -1062
to -1049 (DR2), which are predicted by Li et al.103]
and found the deletion constructs to have no effect on
the promoter activity in the reporter plasmids.52 Li et
al.104 described the presence of putative NF-κB-
binding sites in the human and mouse TSLP gene
promoter (one for the human promoter and two for
the mouse promoter), however, they were located at
different sites from those in the human and mouse
NF-κB regulatory regions reported by Lee et al..52
Redhu et al.98,135 demonstrated that mutation of the
NF-κB or putative AP-1 motif in the ~120 bp of the hu-
man TSLP gene promoter significantly decreased
both TNF-α-induced and IgE-induced promoter activi-
ties in primary human ASMCs. The roles of the IRF-1
and Opaque-2 motifs52 in the human NF-κB regula-
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tory region are unknown.
REGULATION VIA RXR
Li et al.103 demonstrated that, in mice, epidermal KC-
specific ablation of genes for the nuclear receptors
RXRα and RXRβ results in increased TSLP produc-
tion in the skin and an AD-like phenotype. In another
paper,104 they proposed that RXR to be involved in di-
rectly repressing transcription through the binding of
the RXR-VDR-corepressor complex and RXR-RARγ-
corepressor complexes to the mouse TSLP promoter.
Lee et al.106 found that 9-cis-RA, an agonist for RXR,
inhibited IL-1β-induced human TSLP mRNA expres-
sion in 16HBEo− cells. In the presence of 9-cis-RA,
RXR bound to IL-1β-induced NF-κB and prevented it
from binding to oligonucleotide probes containing
the NF-κB consensus motif or the NF-κB binding site
in the human TSLP promoter. Chromatin immuno-
precipitation (ChIP) assays revealed that 9-cis-RA can
block the recruitment of NF-κB to the endogenous
TSLP promoter. In the presence or absence of 9-cis-
RA, the binding of RXR to the putative retinoic acid
responsive element (RARE) in the endogenous hu-
man TSLP promoter (-3912 to -3900) was not detected
by the ChIP assay. These results indicate that 9-cis-
RA-bound RXR acts to repress IL-1β-induced TSLP
gene expression by preventing NF-κB from binding
to the promoter through the binding of 9-cis-RA-
liganded RXR to NF-κB, i.e. inhibition of NF-κB acti-
vation by 9-cis-RA occurs at the level of NF-κB (Fig. 3,
upper) and not at the human TSLP promoter, con-
trary to the model proposed by Li et al..104
ACTIVATION BY VDR AGONISTS
Li et al.104,105 demonstrated that, in mice, skin treat-
ment with the active form of vitamin D3 or its analog
MC903, agonists for VDR, results in increased TSLP
production in the skin and an AD-like phenotype.
They suggested that VDR is involved in directly re-
pressing transcription through binding of the un-
liganded VDR-RXR heterodimer to the mouse TSLP
promoter and that the topical application of the VDR
agonists generates RXR-VDR-coactivator complexes
whose transcriptional activity is efficient enough to
not only relieve the repression exerted by RXR-RARγ-
corepressor complexes but also to further enhance
the basal promoter activity.104 Interestingly, cotreat-
ment with a RARγ-selective agonist (BM961) (Fig. 3,
upper) and a limiting dose of the active form of vita-
min D3 synergistically enhanced the TSLP gene ex-
pression in mouse skin, supporting the model.104
REPRESSION VIA GR
GC can inhibit TSLP production.27,49,107-109 Although
GR-mediated transrepression was generally ascribed
to indirect “tethered” interaction with other DNA-
bound regulators, such as NF-κB and AP1, Surjit et
al.109 reported that GC transcriptionally repressed
TSLP expression in AD mouse models and demon-
strated the repression to be mediated through the di-
rect binding of GR to a simple negative GC response
element (GRE) (Fig. 3, upper), which belongs to a
novel family of evolutionary-conserved cis-acting
negative response elements (IR nGREs) found in nu-
merous GC-repressed genes. ChIP assays revealed
that binding of GC-liganded GR to the mouse TSLP
IR nGRE (IR1 nGRE) (-1352 to -1343) enables the for-
mation of a repressing complex containing SMRT and
NCoR corepressors. Generation of the repressing
complex on the IR1 nGRE precludes the MC903-
induced or all-trans-RA (a RAR agonist)-induced for-
mation of an activating complex including SRC-2 (and
also SRC-3 upon MC903 treatment) and RNA polym-
erase II in DR3d vitamin D response element (VDRE)
(-7370 to -7356), DR2b RARE (-13893 to -13880), and
proximal promoter (PP) (-318 to -8) regions. The
mouse TSLP IR1 nGRE located -1.3 kb upstream from
the PP region can act as a silencer element preclud-
ing the formation of a chromatin loop between the PP
and the DR3d VDRE enhancer region located -7.3 kb
upstream.
SPLICING FORMS
In primary human bronchial ECs, two forms of TSLP
(long and short) have been reported and polyI:C
upregulates the expression of long-form TSLP and in-
duces release of TSLP.136 The role of the human
short-form TSLP is unknown.
FUNCTIONAL ANALYSIS OF SNPs
Harada et al.102,136 found that the promoter SNPs
rs3806933 and rs2289276 are significantly associated
with disease susceptibility in both childhood atopic
and adult asthma. They demonstrated that rs3806933
(-847 C > T), which creates a binding site for AP-1, af-
fects the transcriptional efficiency of the long-form
TSLP induced by polyI:C in primary human bronchial
ECs.136 They also found that rs2289276 (-82 CT) is
located in a binding motif of AP-2α, a possible tran-
scription suppression factor, and demonstrated
higher AP-2α binding to -82 C, which may have re-
duced the transcriptional activity through repressive
effects on transcription.102
SUMMARY
TSLP is expressed mainly by ECs and KCs at barrier
surfaces and is constitutively expressed in the thy-
mus and intestinal ECs (Fig. 1). TSLP expression in
the epidermis, epithelium, and submucosa in skin,
airway, and ocular tissues plays a critical role in the
pathogenesis of allergic diseases. TSLP constitutively
expressed in the human thymus is responsible for
the differentiation of Treg cells. TSLP constitutively
expressed in intestinal ECs via interaction with intes-
tinal commensal microflora may contribute to intesti-
nal homeostasis, a loss of which is observed in pa-
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tients with Crohn disease. Recent studies reported
that various cell types such as mast cells, ASMCs, fi-
broblasts, and DCs can express TSLP. TSLP ex-
pressed in trophoblasts may contribute to maternal-
fetal tolerance. TSLP expression in the tumor mi-
croenvironment contributes to tumor growth. TSLP
expressed in synovial fluid may have a role in rheu-
matoid arthritis.
At barrier interfaces, environmental stimuli such as
allergen sources, viruses, microbes, helminths, diesel
exhaust, cigarette smoke, and chemicals trigger
TSLP production, resulting in initiation of the sensiti-
zation process and the exacerbation of allergic
diseases (Fig. 1). Proinflammatory cytokines, Th2-
related cytokines, and IgE contribute to TSLP pro-
duction (Fig. 2), indicating an amplification cycle for
the Th2 response. TSLP production can be positively
or negatively regulated via nuclear receptors and β2-
adrenoceptor signaling. Skin barrier injury, increased
endogenous protease activity, less Notch signaling,
loss of RXRα and RXRβ expression, and VDR ago-
nists induce TSLP production and, in mice, a Th2 re-
sponse or AD-like inflammation, demonstrating that a
disturbance of epidermal homeostasis triggers TSLP
production and increase in TSLP concentrations in
the epidermis induces the onset of Th2 cytokine-
associated inflammation. Regulation of TSLP expres-
sion by microRNAs and peptidyl-proryl isomerase Pin
1 has been reported (Fig. 3, lower). The transcription
factors NF-κB and AP-1 contribute to TSLP gene ex-
pression (Fig. 3, upper). Nuclear receptors such as
RXRs, RARs, VDR, and GR regulate TSLP gene ex-
pression in the chromatin. Two promoter SNPs asso-
ciated with asthma, which respectively affect binding
of the transcription factors AP-1 and AP-2α, have
been reported. Studies of environmental, endoge-
nous, transcriptional and posttranscriptional regula-
tory mechanisms of TSLP expression will contribute
to the elucidation of the pathogenesis of allergic dis-
eases and other TSLP-related disorders and to the de-
velopment of new approaches in prevention and ther-
apy.
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